The earliest measure of adrenal cortical activity was the 17-ketosteroid excretion, the measurement of which developed from the method employing the Zimmermann reaction worked out by Callow et al. in 1938. For about fifteen years this was the only method available and it held undisputed sway partly for this reason, but also because it appeared to show a correlation, though a crude one, with the clinical diagnosis. Figures were low in hypo-adrenalism and high in virilism and adrenal carcinoma. But the correlation with the degree of virilization was poor and thetechnique of estimation of the colour in urine extracts was very unsatisfactory, and was recognized to be so.
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When methods were ultimately worked out for the separate identification of the individual 17ketosteroids, it became apparent that these varied considerably in chromogenic power, many being very much weaker than the reference steroid often used. It is only relatively recently that the magnitude of the errors concealed in this common clinical estimation has clearly emerged. Goldzieher & Axelrod (1962) have compared the clinical estimate with the actual content of identified individual 17-ketosteroids (17-KS) determined by reliable chromatographic methods. They found that large quantities of non-specific chromogens were present which might account for as much as 80% of the clinical estimate of total 17-KS. In only 16 % of urines was the non-specific chromogen less than 10% of the clinical estimate. They conclude 'the unpredictable admixture of nonspecific chromogens reduces the significance of the clinical "total 17-ketosteroid" determination to little more than a rough approximation'. This unsatisfactory state of affairs has been confirmed by Ernest et al. (1964) so we need have no reason to doubt it.
It is not surprising therefore that the information yielded by the ketosteroid excretion is strictly limited. Ernest et al. (1964) say 'a routine 17-KS determination cannot be expected to accomplish much more than a separation of a low from a high steroid excretion'. This is a good example of the way in which study of adrenal metabolism has been handicapped by unreliable methods. There were early suspicions of this unreliability, for when the adrenal response to stress was first recognized it soon became apparent that this was not reflected in the urinary 17-KS which might even fall during severe stress. It soon became abundantly clear, also, that the various ways of estimating corticosteroid metabolites which were soon after developedthe formaldehydrogenic steroids, the reducing steroids and later also the 17-ketogenic steroids -were all insufficiently sensitive to reveal with clarity the adrenal stimulation known to be provoked by stress. But because there existed no better criteria by which to judge the degree of reliability of such methods the extent of their fallibility remained for many years a matter of mere conjecture. Doubt was expressed mainly as reports of single cases or small series in which the results of the 17-ketogenic steroid excretions (KGS), for example, failed to support the clinical impressions. The very fact that such reports often appeared should perhaps have raised greater doubts than it did. The 17-KGS results were widely accepted if they agreed with expectations, they were apt to be discounted if they disagreed with clinical impression. And if they lagged behind the clinical view, they could hardly be expected to lead it.
It was difficult to find a way out of this impasse until the advent of isotopes rendered possible a great advance in accurate measurement of adrenal activity in terms of daily production. I shall not go into the theory of secretion rate determinations here. In general terms it may be said that the use of the isotope corrects automatically for most vagaries and] variations in steroid metabolism in the individual, and for most variations in renal function. It depends also on a much more precise form of chemical analysis than the 17-KGS, and very probably yields an estimate of the steroid secretion rate which is within 10-15 % of the true value. The use of the isotopic steroid makes it easy to mark in a readily detectable manner all the metabolites of the steroid which leave the body. It then becomes possible to measure with a fair degree of accuracy the total mass of these metabolites either in the urine or leaving the body in other ways. This total mass is considered to be equal to the production rate. And such are the peculiarities of the isotopic methods that it does not greatly matter if many of the metabolites are of undetermined nature, they are nevertheless included in the estimate. Another major characteristic of such isotopic methods is that their accuracy is not appreciably less at low levels of adrenal activity than at normal or high ones. This can often be of considerable clinical advantage, for it is in sharp contrast to nonisotopic methods. Not all adrenal steroid products can be assayed by these methods but luckily cortisol, aldosterone, corticosterone and 1 1-deoxycortisol (S) are among those that can, for all these have actual or potential clinical importance. There is no reason to believe that results are not reliable provided that renal function is reasonably good and that rapid changes are not occurring in adrenal activity. If they are, an appreciable lag will result in the apparent change, due to the delay which occurs in the elimination of steroid as of other metabolites in the urine. But this is a handicap common to all methods depending on urine analysis, and does not prevent serial secretion rate estimations on the human subject, provided the existence of this lag is clearly recognized (Cope & Pearson 1965) .
We have been criticized at times because we have for the past seven years advocated the giving of the isotopic steroid dose orally rather than by intravenous injection. It has been suggested that poor absorption may interfere with the oral route, but this has not been our experience. The theoretical objection has been raised that orally absorbed steroid goes straight to the liver where much of it is destroyed before it enters the systemic circulation, whereas the intravenous route introduces the whole dose into the systemic circulation. That this theoretical objection is not significant in practice, we have been able to show clearly in the following way: There are now available supplies of cortisol labelled with either tritium or 14C. The fate of both these isotopes can be separately and quite independently followed in the body and in the cortisol metabolites. Hence if cortisol labelled with one isotope is given by mouth and cortisol labelled with the other is given intravenously at the same time it is possible to compare the secretion rate estimates derived from both routes simultaneously in the same patient. It is found that a negligible difference exists between the results obtained by the two routes (Cope & Pearson 1965) . We use the oral route where possible, not only for its convenience, but also because the intravenous injection may arouse adrenal activity in some sensitive subjects.
We have come to regard the cortisol secretion rate as the final arbiter in the diagnosis of hypercorticism. A result which is only slightly above the upper normal limit probably does not indicate the need for definitive therapy. This is not to say that well raised cortisol secretion rates are indications for remedial therapy. This must be decided on clinical grounds, having due regard to the symptoms, the degree of disability and future risks to the patient. It must be remembered also that other causes for a raised cortisol secretion rate can exist, such as obesity or hyperthyroidism.
If we define Cushing's syndrome as a state of overproduction of cortisol it follows that a cortisol secretion rate which is not elevated excludes the diagnosis. In all of a series of 26 proved cases of hyperplasia, all actively treated later either by adrenalectomy or by pituitary implant, the cortisol secretion was above 35 mg daily. When values between 25 and 35 mg are encountered it is unlikely that the clinical condition will often be of such severity as to demand active therapy. Such borderline or ambiguous cases seem to be of three main types: a few are simple obesity, a few are very mild examples of hypercorticism which never progress and which may subside without final diagnosis, and a small number are those who are encountered in the early stages of a progressively developing Cushing's syndrome. We have encountered two cases of the latter type in which both clinical state and secretion rate figure were ambiguous when first seen, yet both of whom developed clear Cushing's syndrome one or two years later.
The cortisol or other steroid secretion rate is by far the most accurate measure of adrenal cortical activity available today. It is eminently suitable, therefore, to be used as a standard of reference against which to judge the reliability of the very many other simpler clinical methods which are in routine clinical use. Considering that the secretion rate technique has been available for seven years or so, it is remarkable how little of such testing has yet been done. As long ago as 1959 we reported that in our hands the correlation between cortisol secretion and 17-ketogenic steroid excretion was disappointingly poor (Cope & Black 1959) .
It is still generally true that the cortisol secretion rate is very approximately twice the ketogenic steroid output. But the scatter when points are plotted is very large. From our own data on 28 patients with Cushing's syndrome due to hyperplasia we assess the probability of a cortisol secretion rate being above 35 mg, i.e. probably needing treatment, as almost 100% when the 17ketogenic steroid excretion is above 20 mg. In the majority of such cases the clinical picture will be fairly characteristic and make the diagnosis very probable if not quite certain. In such cases the 17-KGS can offer valuable confirmation of the diagnosis.
The 17-ketogenic steroid excretion is by no means always raised so clearly, for among a consecutive series of 33 cases of Cushing's syndrome, all of whom had cortisol secretions of 35 mg daily or higher, the 17-KGS excretion was below 15 mg, i.e. in the accepted normal range, in 7 (20 %). In these cases, therefore, the urinary 17-KGS would have given actively misleading results.
Clinical uncertainty in diagnosis is most likely to arise in cases having cortisol secretion rates between 25 and 35 mg and it is here that 17-KGS assay fails more seriously. In 12 such borderline cases, in which cortisol secretion lay between these limits, the urine 17-KGS varied between 4 and 17 mg. In 5 of these cases it-was below 10 mg and could therefore have led to erroneous conclusions. Nor is it safe to assume that a 17-KGS excretion below 17-5 mg indicates a normal or near normal cortisol secretion, for among 56 such subjects we have encountered 9 with secretion rates between 35 and 60 mg, all of whom were clinical examples of florid Cushing's syndrome. These results therefore give numerical expression to what many have felt, namely that the 17-KGS assay is an unreliable test whose results are accepted when they agree with clinical impression, but are discounted when they do not. The use of tests of this type may give moral support to the clinician, but can scarcely be expected to sharpen his diagnostic skill.
I am not aware of any comparison of the clinical 17-KGS result with the true content of ketogenic steroids determined more carefully, but a comparison of this type has been made with the urinary Porter-Silber chromogens so widely used in the United States for the same clinical purpose. Ernest et al. (1964) , who made this comparison, concluded that, as with the 17-KGS determination, 'the significance of individual determinations is low, and such routine determinations do not afford much more than a distinction between a high and a low excretion of steroids'.
If then the 17-KGS determination seems so unreliable in practice, in spite of its apparent validity in theory, it seems justifiable to search for simpler tests in the hope that they may prove to be no worse. It was with this in mind that Mattingly, Dennis, Pearson and I (1964) were encouraged, though with little hope, to explore the use of the acid fluorescence of steroids in urine because it had proved so helpful in plasma. The only reliable and reasonable criterion by which to judge this simpler test was the isotopically determined cortisol secretion rate. Greatly to my surprise, and quite contrary to our expectations, a quite reasonable correlation was revealed between the two. In spite of the speed and simplicity of the estimation, the correlation with the cortisol secretion rate was considerably better than was that of the 17-KGS. The correlation is a purely empirical one, although the main contributors to the fluorescence seem to be cortisol, corticosterone and 20-hydroxycortisol in varying proportions.
The triparanol story is an excellent example of the way in which reliance on urinary assays may lead one sadly astray.
Triparanol was originally introduced for the lowering of cholesterol in cardiovascular disorders. In 1961 an American team found that the drug reduced the output of urinary 17-OHCS and 17-KGS by 40-50%. A reduction of about 30% was also found in the excretion of aldosterone metabolites. Further work by the same group showed that the response of the urinary 17-KGS to corticotrophin stimulation was also greatly reduced. The conclusion was therefore drawn that adrenal cortical activity was suppressed by the drugs. This team accordingly advocated use of the drug for the treatment of Cushing's syndrome, and indeed actually treated 6 cases for periods up to five months. But it was soon found elsewhere that the drug did not in fact reduce the level of plasma cortisol. Its value in producing a suppression of adrenal function was therefore doubted. The action of this drug was eventually elucidated by some excellent experiments in which it was shown that the cortisol secretion rate and the aldosterone secretion rate were both completely unaffected by the drug, which was in fact completely devoid of any action on the adrenal cortex.
It was possible to show quite clearly that the drug was in fact interfering with the excretion of the steroid metabolites into the urine.
The modern rapid plasma cortisol methods (Mattingly 1962) have been subjected to criticism, levelled against them on grounds of their specificity. But this is true of many clinical methods in routine use and reliability must always be considered in the context of the proposed uses for the methods. The method estimates mainly 1 1-hydroxylated corticosteroids. In our own laboratory Dr Mattingly and his successors have carried out several thousand estimations by the simple methods. Suspect figures have been, I estimate, less than 1 %. There is a small but significant blank value in plasma presumed to contain no cortisol but it is commonly less than 2-5 ,ug/100 ml. It is due presumably to nonspecific substances, but this should not be allowed to detract from its clinical use. It is well to recall that a far larger percentage of nonspecific contaminant was tolerated in the first twenty years of blood sugar methods, and this did not seriously detract from their value in control of, or study of, diabetes. Nor did the non-specific chromogen in plasma creatinine detract from its use in the early investigation of renal function. Perhaps the most carefully checked of plasma corticosteroid methods is that of Peterson et al. (1957) , in the checking of which isotopic control was used, and for which a very acceptable accuracy was demonstrated. The simple fluorescent plasma 1 1-OHCS method has been checked against this and found to give a correlation coefficient of 097. Experience with the method has given us no reason to mistrust it. On the contrary there are a number of clinical situations in which it can be especially valuable. One of these is in the differentiation between obesity and Cushing's syndrome. The difficulty in diagnosis here derives from the fact that many obese persons show not only a high output of 1 7-ketogenic steroids, but also a cortisol secretion rate raised well up towards the Cushing's syndrome range. Differentiation is then best made by demonstration of a normal diurnal behaviour of the plasma cortisol in the obese, and this study can be completed within twenty-four hours. In Cushing's syndrome the late evening plasma cortisol has very high diagnostic value and rarely fails.
Another valuable use for the plasma cortisol is in the non-endocrine case which does not respond as well as expected to steroid therapy. In such situations, which are by no means uncommon, it is very convenient to be able easily and rapidly to estimate the plasma 1l-OHCS because, if the steroid therapy is by prednisone or other synthetic analogue, the 1 -OHCS will be depressed to quite low levels. If they are not, then suspicion that the steroid tablets are not being adequately absorbed should be strong. We would regard it as good reason for changing to a different preparation. A number of cases of poor therapeutic response referable to poor tablet absorption have been revealed by this means.
Yet another use for plasma cortisol determination is in the measurement of reactions to the dexamethasone suppression test. There are several reasons why the reaction in plasma is better than tests in urine. It was shown by us as long ago as 1955 (Cope & Harrison 1955 ) that in an occasional case of Cushing's syndrome the inhibition might be too slight to be revealed by the relatively slowly changing urinary metabolites, yet might show in the urine cortisol. This implies that a transient fall in plasma level has occurred in such cases. It is well known that escape from the suppression occurs if the inhibitory steroid is continued long enough. Another advantage is the speed with which an answer can be obtained. I gather that it is a feasible proposition to perform the suppression test on an outpatient and have the result the same evening. This clearly offers great advantages in many centres. But failure to suppress the plasma ll-OHCS certainly does not exclude a hyperplasia completely.
In theory the measurement of plasma 1 -OHCS should facilitate diagnosis of acute adrenal failure of any type, and I shall return to this point, but in practice the usual and often desirable course is to treat first on suspicion and to diagnose after, so that its practical value is limited in this situation to the diagnosis in retrospect.
The plasma cortisol (1 -OHCS) concentration cannot be used to measure response to metyrapone. The test is intended to provoke an increase in ACTH secretion, and the evidence that this has occurred must be an enhanced adrenal activity. Under the 1 1-hydroxylase inhibition of metyrapone this activity will produce mainly 1 1-deoxycortisol (S) which is not estimated by the fluorescent method. The enhanced activity cannot therefore be revealed by the 1 I-OHCS method. All that can be shown is that some adrenal poisoning has been induced. My immediate purpose is to point out the major limitation of the plasma 11-OHCS method for this particular purpose.
Post-operative collapse: In 1961 a case was reported (Sampson et al. 1961 ) of a man who had been on 10 mg prednisone for six months. He collapsed after a laparotomy, his blood pressure falling to low levels. A prompt recovery followed I.V. cortisol. A second operation later led to a second collapse. The importance of this case lies in the fact that during both collapses the plasma cortisol was actually measured and reported to be below 5 ,ug/100 ml. The authors were able to point out that, with the possible exception of one other case, no plasma cortisol levels in post-steroid therapy collapse had been reported before. This is indeed a remarkable state of affairs, for feasible methods for estimation had been available for about eiglht years. Yet the literature is generously sprinkled with reports of cases of post-operative collapse in which'hypo-adrenalism was alleged or assumed or claimed, either on grounds of probability or because a good response to intravenous therapy with cortisol was obtained. Quite a' number of papers have appeared reporting cases of alleged hypo-adrenal collapse in which no steroid data were offered in support of their claims.
To regard response to I.V. cortisol as evidence of hypo-adrenalism is quite unjustified; it is a deduction not supported by any good evidence and there is, indeed, plenty to show that it is a fallacious deduction. It is well established, for example, that withdrawal symptoms, even severe ones, can occur in persons who still have normal plasma corticosteroid levels. Yet they may respond clearly to re-started steroid therapy.
Since we must conclude that before the report of Sampson et al. the diagnosis of post-steroid hypo-adrenal collapse was always purely speculative, it is clear that no evidence could have existed correlating response to steroids with true adrenal failure. It was a pure guess. To obtain more definite evidence will inevitably be difficult, because such collapses occur in awkward places and at awkward times. But it is necessary for far more plasma cortisol estimations to be made in such situations before the true position can be properly assessed. Mattingly, when working at Hammersmith, was able to obtain plasma samples from several cases of post-operative collapse, some of whom rallied well in response to intravenous cortisol. Yet in none of these was the plasma cortisol low and in most it was raised well into the stress range. Moore (1957) states: 'In terms of clinical surgery, adrenal insufficiency must be watched for and guarded against; but to consider this as a common denominator in all surgical disaster is to neglect the diagnostic challenge of the sick surgical patient.' Moore has pointed out that collapse after a minor operation is more likely to have an adrenal cause than is collapse after major surgery. Yet in spite of the evidence of sustained plasma cortisol concentrations in the great majority of these cases of collapse, there is a steady body of clinical opinion believing that post-operative collapse is more frequent after surgery in patients who have received steroid therapy. There is here a major ambiguity which will require much more data for its resolution. The rapid plasma methods offer an excellent tool by which this can be done, but the close collaboration of surgeons and anxsthetists will be necessary. It may be that during long steroid therapy the tissues become adjusted to need a higher steroid concentration, so that a fall towards normal levels represents a relatively hypo-adrenal state for that individual's tissues. Such an adaptation tends to occur in the diabetic with hyperglyczemia. This is pure speculation at present for cortisol, but the techniques are now available for its investigation.
Metyrapone action: When the action of this drug was first worked out in 1958 cogent facts were collected all of which were in conformity with the general view that it had a strongly selective inhibitory effect on the action of 1 1-3-hydroxylase enzyme. There is still no reason to doubt that this occurs but, although the qualitative change may be accepted, the quantitative aspects must still be regarded as highly unsatisfactory. The theory behind the metyrapone test is clear. It is to handicap the production of cortisol so much that plasma levels fall, thereby providing a stimulus to increased corticotrophin production and so to enhanced adrenal activity above that prevailing with a normal plasma cortisol. The real ideal was to abolish cortisol production entirely, so that a maximal stimulus to the corticotrophin release mechanism was created. The early investigations published appeared to confirm that this indeed occurred. Plasma cortisol was reported to fall to low levels quite rapidly, usually within four hours. Likewise the metabolites tetrahydrocortisol and tetrahydrocortisone were reported to disappear from the urine though this took much longer owing to the slower rate of elimination of these metabolites by the kidney. But criticisms arise both from the scattered reports of results at variance with clinical expectations and from the obtaining of more definitive evidence of incomplete action of the drug.
One of the interesting clinical discrepancies was in myxcedema where one group of workers (Liddle 1960) found no reduction in pituitary responsiveness, whereas another group found the subnormal responses which one would expect to occur in this condition (Gold et al. 1960) . A search for increased corticotrophin in the plasma did not always show the expected rise, although the methods used were sensitive enough. Several workers reported that the fall in plasma cortisol which should occur did not always do so (Waxman et al. 1961) . And Mattingly (personal communication) , working at Hammersmith, found no fall in the plasma cortisol level after twenty-four hours on metyrapone in 9 of 13 cases of Cushing's syndrome due to hyperplasia, although in 3 of these 9 there was a temporary fall at six hours. Nor could the desired result be achieved satisfactorily by increasing the dose up to the limits of tolerance, for in one study (Schneider 1964 ) even 4 5 g in a day failed to provoke a proper response in one of 10 quite normal subjects. It is clear that reliable criteria of proper dosage have not been defined. But still more cogent evidence that the expected effect was not achieved was produced by Lazarus et al. (1963) who reported that the cortisol secretion rate on the second day of a course of metyrapone was still frequently in the normal range, and that this was true even with maximal doses of the drug. We were able to confirm this finding, and it is therefore very clear that the drug is not doing in the body what is commonly expected of it. Dennis and I have therefore used the isotopic methods of precise measurement in an effort to throw light on the reasons for these great ambiguities.
Under the influence of the 11-hydroxylase inhibition of metyrapone, the gland produces 11deoxycortisol (S) in place of cortisol, and the production of the former seems to be the direct result of interference with the synthesis of the latter. Our initial problem was to measure the production rates of both these compounds simultaneously. Trial studies in 'cross-over' experiments soon showed that each metabolic pathway maintained its individuality sufficiently sharply, and that the simultaneous determination of the two secretion rates was feasible. There is a small production of S from the human adrenal cortex even in normal persons, about 0'8 mg daily, or about 5 % of the cortisol production. We may say, therefore, that normally the efficiency of cortisol production is 95% complete, only 5 % failing to obtain its 1 1-hydroxylation. Under the influence of metyrapone this percentage rises until 95 % or more of the total product fails to gain the 11hydroxyl group. The 1 1-hydroxylase system is poisoned and it is convenient and valid to express the severity of this poisoning in this way, the figure being derived quite simply from the formula 100 S/(F+S) % where F and S are the respective secretion rates of the two steroids. We have measured the degree of poisoning produced by various doses of metyrapone, es- pecially the often used dose 3 g daily. We find that the mean degree of poisoning for this 3 g dose is about 86 % but that there is considerable scatter among individuals and the values vary from 66 % to 90% poisoning or more. Another point that emerges from these studies is that the cortisol secretion rate is quite well maintained, the mean secretion during a daily dose of 3 g metyrapone being over 10 mg, a figure below the normal mean but within the normal range. The adrenal cortex is clearlyrevealingtheremarkableadaptabilitywhich characterizes most living tissues. Handicapped by the poisoning effect of the metyrapone, the gland still strives with its remaining traces of effective 1 1-f-hydroxylase to maintain as near a normal cortisol output as possible. In the process of doing this it produces as a by-product increasing amounts of tetrahydro-S. The amount of this byproduct will not depend only on the magnitude of the stimulus, but also on the severity of poisoning.
If the degree of poisoning be known then the amount of S or of ketogenic steroids formed can be predicted roughly. Thus with 90% poisoning the gland will need to produce 90 mg of S for every 10 mg of cortisol formed.
In practice the cortisol secretion is almost, but not quite, maintained. The phenomenon follows the general lines shown in Fig 1. If the poisoning rises from 90 to 95 %, a doubling of the activity and a doubling of the S production will be called for. A very small reduction in poisoning will thus enormously reduce the response as observed in the ketogenic steroid excretion. The observed secretion of cortisol + 1 1-deoxycortisol (S) on a daily dose of 3 g metyrapone varies between 28 and 110 mg daily. This means that for the lower figure the 17-ketogenic steroid excretion will theoretically be only slightly above normal. But there are big inaccuracies in this estimation, and a poor correlation with cortisol secretion rate. We can conclude that even in normal individuals a 3 g dose of metyrapone will not necessarily raise 1 7-KGS excretion recognizably above the normal range, and this is what has indeed been found. The magnitude of the metyrapone response, when properly measured, is determined by two independent variables, (a) the sensitivity of the corticotrophin release mechanism, and (b) the degree of poisoning achieved, and of these the latter may sometimes be the more important. I suggest, therefore, that it is not safe to draw deductions from the magnitude of a metyrapone response, regardless of the way in which it is measured, but that conclusions can only be drawn from its presence or absence, and even then they may occasionally be misleading. A more precise measure of the corticotrophin response will necessitate simultaneous determination of the degree of poisoning, but this will complicate the test enough to put it outside the realm of feasible routine clinical use. When a clear rise in 17-KGS excretion is achieved in the metyrapone test corticotrophin release sensitivity can be accepted, and in many clinical situations this can be very valuable, especially in Cushing's syn-drome, to establish corticotrophin dependence. But no conclusions should be drawn from a failure to elicit a positive response, since this is almost within the range of normal reaction.
The clinical endocrinologist has worked for too long with laboratory methods which were not giving him information as reliable as he was entitled to expect. The position has now changed. It is possible to assess the reliability of urinary analysis tests by comparing them with something far more valid than clinical impression. It is now possible to obtain plasma cortisol estimations rapidly and with acceptable clinical accuracy. It is to be hoped that these opportunities will be widely used to bring a higher precision to clinical diagnosis.
